Alvetex Scaffold 384 well plates used in an Oncology HTS program by AstraZeneca
8 October 2014
Scientists at AstraZeneca in the UK have compared the activity of a diverse compound set in 2D and 3D cell cultures using Alvetex® Scaffold 384 well plates in an automated Oncology HTS (High Throughput Screening) setting.
AstraZeneca reported that Alvetex Scaffold 384 well plates were:
Easy to use with a workflow similar to 2D cell culture plates
Compatible with HTS automation, dispensing and read-outs
More feasible and cost effective than currently available alternative 3D culture platforms
The team at AstraZeneca presented the data at the recent ELRIG drug discovery meeting as a talk and poster entitled: “Side by side: An evaluation of 2D vs. 3D cell culture for High Throughput Screening in Drug Discovery.” The poster presentation demonstrates the use of Alvetex Scaffold 384 well 3D cell culture plates for an Oncology focussed HTS program.
Note:Reinnervate Ltd (County Durham, England) was acquired by REPROCELL Inc (Yokohama, Japan) in August 2014. Biopta Ltd (Glasgow, Scotland) was acquired by REPROCELL in November 2015. REPROCELL Europe Ltd was established by merging Reinnervate and Biopta in June 2016.